Skip to content
Home/Companies/Oxford BioTherapeutics

Oxford BioTherapeutics

·United Kingdom·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Oxford BioTherapeutics?

Oxford BioTherapeutics is a British company, currently owned by ALSA Ventures since 2019 and Oxford Capital.

Hand-verified · updated 2026-09-29

Open JSON · CC-BY
ALSA Ventures
Most recent investor
ALSA Ventures
ALSA Ventures European Biotechnology Fund · 2020 · Life Sciences VC
2 ownership periods · full history below

Key facts

HQUnited Kingdom
StatusActive

Ownership history

2 ownership periods

Active
Co-held by ALSA Ventures and Oxford Capital since 2019.
ALSA Ventures
ALSA VenturesActive
2019 · present(7yr) · ALSA Ventures European Biotechnology Fund · 2020 · Life Sciences VC
Oxford Capital
Oxford CapitalActive
present · Oxford Capital Growth EIS · 1999 · Evergreen

More from ALSA Ventures European Biotechnology Fund

Other portfolio companies in the same fund.

ReproNovo
Active
BiotechSwitzerland· 2025
Axovia Therapeutics
Axovia Therapeutics
Active
BiotechUK· 2023
Vantage Biosciences
Vantage Biosciences
Active
BiotechUK· 2023
Promatix
Active
BiotechUK· 2021
Montis Biosciences
Montis Biosciences
Active
BiotechBelgium· 2020
Epsilogen
Epsilogen
Active
BiotechUK· 2018

Questions

Who owns Oxford BioTherapeutics?

Oxford BioTherapeutics is currently owned by ALSA Ventures and Oxford Capital, through ALSA Ventures European Biotechnology Fund, since 2019.

When did ALSA Ventures and 1 other acquire Oxford BioTherapeutics?

ALSA Ventures and 1 other acquired Oxford BioTherapeutics in 2019.

Who has owned Oxford BioTherapeutics over time?

Oxford BioTherapeutics has been through 2 private-equity ownership periods: ALSA Ventures · via ALSA Ventures European Biotechnology Fund · since 2019; Oxford Capital · via Oxford Capital Growth EIS.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue